TESARO is an oncology-focused biopharmaceutical company.
TESARO is dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products.
Contact
TESARO Bio GmbH.
Poststrasse 6
6300 ZUG
Switzerland
| www.tesarobio.com
|
Kari Sarvanto outlines his journey from leading PRIMEX to establishing CRAB, a preclinical oncology company focused on non-toxic cancer treatments. Sarvanto highlights his strategic leadership background, the innovative approach of…
Rahul Sahgal brings over 20 years of experience in both the private sector and government to his role as CEO of the Swiss-American Chamber of Commerce, uniquely positioning him to…
Switzerland is widely praised for its excellent universal healthcare system and strong pharma sector. Seen as a bastion of efficiency and innovation, the country is nonetheless falling behind its European…
Daniel Weber of Boehringer Ingelheim Switzerland explores the company’s strategic initiatives and focus on innovation within the Swiss healthcare system. Weber emphasizes Boehringer Ingelheim’s long-term vision of transforming lives, its…
Incyte’s Jonathan Dickinson discusses the company’s mission to address unmet medical needs in oncology and autoimmune diseases while expanding its footprint across Europe. He highlights the strategic role of Incyte’s…
Johnson & Johnson Innovative Medicine’s Max Pahlow discusses how the company’s commitment to innovation and patient care drives its success in Switzerland. He highlights the importance of advancing clinical trials,…
World-renowned oncologist Professor Susan Gasser outlines the innovative public-private partnership model in place at the ISREC Foundation at the AGORA Cancer Research Center in Lausanne. The unique model of ISREC/AGORA…
Dr Frank Ruhli discusses the importance of attracting top talent and fostering academic freedom as key factors in achieving research excellence. Ruhli highlights his collaborative leadership style, significant achievements like…
Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s…
The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive…
Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s…
Hans Peter Borger of Spirig HealthCare discusses the company’s integration with the STADA Group and its focus on generics, consumer healthcare, and specialty markets, including Parkinson’s and rare diseases. He…
See our Cookie Privacy Policy Here
